By Karen Blum
Since cefotaxime—the preferred cephalosporin in neonates—was discontinued in 2018, many hospital neonatal ICUs (NICUs) have switched to ceftazidime or cefepime. But a recent study of more than 50,000 neonates indicates that these alternatives could lead to increased adverse events, with a significantly higher proportion of babies developing sepsis, necrotizing enterocolitis (NEC) or dying, compared with those given cefotaxime.
The study “added to some of my